1. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data. (March 2023) Authors: Asselah, T.; Lampertico, P.; Aleman, S.; Bourliere, M.; Streinu-Cercel, A.; Bogomolov, P.; Morozov, V.; Stepanova, T.; Lazar, S.; Suri, V.; Manuilov, D.; Mercier, R.C.; Tseng, S.; Ye, L.; Flaherty, J.F.; Osinusi, A.; Brunetto, M.; Wedemeyer, H. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗